Effects of N-(4-Hydroxyphenyl)retinamide on Vitamin A Metabolism in Rats

William R. Adams, John Edgar Smith, Michael Henry Green

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Chronic administration of the anticancer drug N-(4-hydroxyphenyl)-retinamide (4-HPR) causes reductions in the plasma levels of vitamin A and its transport protein, retinol-binding protein. Here, we used model-based compartmental analysis to study effects of 4-HPR on the whole-body kinetics of vitamin A metabolism in rats. Rats (n = 8) were fed a purified diet containing vitamin A (∼49 nmol retinol/day) plus 0 or ∼50 μmole 4-HPR/(kg body wt · day). Plasma retinol kinetics were monitored for 35 days after intravenous administration of [3H]retinol-labeled plasma. 4-HPR caused an 80% reduction in plasma retinol; after 40 days of treatment with 4-HPR, liver vitamin A levels were 2.33 times higher than those of control rats. A three compartment model, in which plasma retinol exchanges with two extravascular compartments, was required to fit data for both groups. Vitamin A input was via the central plasma compartment, while irreversible loss was via the larger extravascular compartment. The time retinol spent in plasma before reversible or irreversible exit was normal (1.7 hr) in 4-HPR-treated rats, but the rate of plasma retinol turnover was reduced, and the recycling of retinol to plasma was delayed and reduced. Vitamin A utilization was significantly lower in 4-HPR-treated rats (20 nmol retinol/day vs 42 nmol/day in controls). We conclude that 4-HPR partially blocks access and thus binding of retinol to retinol-binding protein and may therefore lead to vitamin A accumulation in certain cells.

Original languageEnglish (US)
Pages (from-to)178-185
Number of pages8
JournalProceedings of the Society for Experimental Biology and Medicine
Volume208
Issue number2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Fenretinide
Vitamin A
Metabolism
Rats
Plasmas
Retinol-Binding Proteins
Rat control

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Adams, William R. ; Smith, John Edgar ; Green, Michael Henry. / Effects of N-(4-Hydroxyphenyl)retinamide on Vitamin A Metabolism in Rats. In: Proceedings of the Society for Experimental Biology and Medicine. 1995 ; Vol. 208, No. 2. pp. 178-185.
@article{e7b2319c343c4e6c8c0e627384ac2fa5,
title = "Effects of N-(4-Hydroxyphenyl)retinamide on Vitamin A Metabolism in Rats",
abstract = "Chronic administration of the anticancer drug N-(4-hydroxyphenyl)-retinamide (4-HPR) causes reductions in the plasma levels of vitamin A and its transport protein, retinol-binding protein. Here, we used model-based compartmental analysis to study effects of 4-HPR on the whole-body kinetics of vitamin A metabolism in rats. Rats (n = 8) were fed a purified diet containing vitamin A (∼49 nmol retinol/day) plus 0 or ∼50 μmole 4-HPR/(kg body wt · day). Plasma retinol kinetics were monitored for 35 days after intravenous administration of [3H]retinol-labeled plasma. 4-HPR caused an 80{\%} reduction in plasma retinol; after 40 days of treatment with 4-HPR, liver vitamin A levels were 2.33 times higher than those of control rats. A three compartment model, in which plasma retinol exchanges with two extravascular compartments, was required to fit data for both groups. Vitamin A input was via the central plasma compartment, while irreversible loss was via the larger extravascular compartment. The time retinol spent in plasma before reversible or irreversible exit was normal (1.7 hr) in 4-HPR-treated rats, but the rate of plasma retinol turnover was reduced, and the recycling of retinol to plasma was delayed and reduced. Vitamin A utilization was significantly lower in 4-HPR-treated rats (20 nmol retinol/day vs 42 nmol/day in controls). We conclude that 4-HPR partially blocks access and thus binding of retinol to retinol-binding protein and may therefore lead to vitamin A accumulation in certain cells.",
author = "Adams, {William R.} and Smith, {John Edgar} and Green, {Michael Henry}",
year = "1995",
month = "1",
day = "1",
doi = "10.3181/00379727-208-43849",
language = "English (US)",
volume = "208",
pages = "178--185",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "2",

}

Effects of N-(4-Hydroxyphenyl)retinamide on Vitamin A Metabolism in Rats. / Adams, William R.; Smith, John Edgar; Green, Michael Henry.

In: Proceedings of the Society for Experimental Biology and Medicine, Vol. 208, No. 2, 01.01.1995, p. 178-185.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of N-(4-Hydroxyphenyl)retinamide on Vitamin A Metabolism in Rats

AU - Adams, William R.

AU - Smith, John Edgar

AU - Green, Michael Henry

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Chronic administration of the anticancer drug N-(4-hydroxyphenyl)-retinamide (4-HPR) causes reductions in the plasma levels of vitamin A and its transport protein, retinol-binding protein. Here, we used model-based compartmental analysis to study effects of 4-HPR on the whole-body kinetics of vitamin A metabolism in rats. Rats (n = 8) were fed a purified diet containing vitamin A (∼49 nmol retinol/day) plus 0 or ∼50 μmole 4-HPR/(kg body wt · day). Plasma retinol kinetics were monitored for 35 days after intravenous administration of [3H]retinol-labeled plasma. 4-HPR caused an 80% reduction in plasma retinol; after 40 days of treatment with 4-HPR, liver vitamin A levels were 2.33 times higher than those of control rats. A three compartment model, in which plasma retinol exchanges with two extravascular compartments, was required to fit data for both groups. Vitamin A input was via the central plasma compartment, while irreversible loss was via the larger extravascular compartment. The time retinol spent in plasma before reversible or irreversible exit was normal (1.7 hr) in 4-HPR-treated rats, but the rate of plasma retinol turnover was reduced, and the recycling of retinol to plasma was delayed and reduced. Vitamin A utilization was significantly lower in 4-HPR-treated rats (20 nmol retinol/day vs 42 nmol/day in controls). We conclude that 4-HPR partially blocks access and thus binding of retinol to retinol-binding protein and may therefore lead to vitamin A accumulation in certain cells.

AB - Chronic administration of the anticancer drug N-(4-hydroxyphenyl)-retinamide (4-HPR) causes reductions in the plasma levels of vitamin A and its transport protein, retinol-binding protein. Here, we used model-based compartmental analysis to study effects of 4-HPR on the whole-body kinetics of vitamin A metabolism in rats. Rats (n = 8) were fed a purified diet containing vitamin A (∼49 nmol retinol/day) plus 0 or ∼50 μmole 4-HPR/(kg body wt · day). Plasma retinol kinetics were monitored for 35 days after intravenous administration of [3H]retinol-labeled plasma. 4-HPR caused an 80% reduction in plasma retinol; after 40 days of treatment with 4-HPR, liver vitamin A levels were 2.33 times higher than those of control rats. A three compartment model, in which plasma retinol exchanges with two extravascular compartments, was required to fit data for both groups. Vitamin A input was via the central plasma compartment, while irreversible loss was via the larger extravascular compartment. The time retinol spent in plasma before reversible or irreversible exit was normal (1.7 hr) in 4-HPR-treated rats, but the rate of plasma retinol turnover was reduced, and the recycling of retinol to plasma was delayed and reduced. Vitamin A utilization was significantly lower in 4-HPR-treated rats (20 nmol retinol/day vs 42 nmol/day in controls). We conclude that 4-HPR partially blocks access and thus binding of retinol to retinol-binding protein and may therefore lead to vitamin A accumulation in certain cells.

UR - http://www.scopus.com/inward/record.url?scp=0028873250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028873250&partnerID=8YFLogxK

U2 - 10.3181/00379727-208-43849

DO - 10.3181/00379727-208-43849

M3 - Article

C2 - 7831350

AN - SCOPUS:0028873250

VL - 208

SP - 178

EP - 185

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 2

ER -